Search Results

You searched for : TreatmentforHIV

	ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology Halozymeâ€™s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every three months and up ... Jun 22
	Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug, Truvada Tablets, 200 mg/300 mg, of Gilead Sciences... Jan 15
	ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe Tivicay contains dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV... Jan 15
	ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay ... Jan 13
	ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe This authorization represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the ... Dec 21
	ViiV Healthcare announces positive CHMP opinion for Rukobia, for the treatment of adults with multidrug-resistant HIV Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.... Dec 11
	Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option with Focus on Women... Nov 16
	ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV ViiV Healthcare announced CHMP issed positive opinion recommending Vocabria in combination with Rekambys and Edurant for the treatment of HIV-1 ... Oct 16
	Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir With Doravirine for HIV-1 Merck, today announced Week 96 data from the Phase 2b trial evaluating the efficacy and safety of islatravir for HIV-1 infections... Oct 08
9 Matching result(s) found!

-Advertisements-

Trending Now
	Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
	International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
	The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
	Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
	Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
	In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
	Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
	Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
	10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
	Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
	The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
	Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
	A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
	The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
	ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
	The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
	Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
	Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
	AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
	Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024

Search Results

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology

Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

ViiV Healthcare receives EU Marketing Authorisation for Tivicay, a treatment for children living with HIV in Europe

ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

ViiV Healthcare announces positive CHMP opinion for Rukobia, for the treatment of adults with multidrug-resistant HIV

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir With Doravirine for HIV-1

Trending Now